

Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks

NCT07093138

Status	RECRUITING
Phase	Phase 4
Sponsor	Alasht Pharmed
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (7)

- Males and females with age of 18 to 55 years
- Age of migraine onset \geq 50 years
- Having a diagnosis of migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year
- Having a history of 2-8 attacks per month
- Remaining stable on prophylactic medication (if used) during the 2 months prior to screening and throughout the study period ... and 2 more (see full listing online)

Exclusion (11)

- Having a diagnosis of other primary (cluster and tension) and secondary headache disorders
- Having a history of chronic migraine headache
- History of resistant or refractory migraine headaches based on European Headache Federation consensus
- Receiving any abortive medication for the treatment of migraine within 48 hours before using Canvert-M
- History of psychiatric and neurologic disorders (except migraine) or any medical comorbid conditions that interfere with the study results
- ... and 6 more (see full listing online)

Locations (1 total)

Tehran Province, Tehran, Imam Khomeini Street (RA) - Before Hassan Abad Square, Tehran, Iran